uniQure N.V. (NASDAQ:QURE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Monday, July 24th.
Other research analysts also recently issued research reports about the company. Oppenheimer Holdings, Inc. set a $17.00 price objective on uniQure N.V. and gave the company a “buy” rating in a research note on Tuesday, May 16th. Jefferies Group LLC reissued a “hold” rating and set a $8.00 target price on shares of uniQure N.V. in a research report on Wednesday, April 12th. Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Zacks Investment Research downgraded shares of uniQure N.V. from a “buy” rating to a “sell” rating in a research report on Wednesday, May 17th. Finally, Chardan Capital set a $13.00 target price on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Sunday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.04.
Shares of uniQure N.V. (QURE) traded up 1.80% on Monday, hitting $8.50. 91,071 shares of the stock traded hands. The stock’s market cap is $216.27 million. The stock has a 50 day moving average of $7.31 and a 200-day moving average of $6.08. uniQure N.V. has a 1-year low of $4.72 and a 1-year high of $9.72.
uniQure N.V. (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 135.97%. The firm had revenue of $4.94 million during the quarter, compared to analyst estimates of $2.92 million. On average, equities research analysts expect that uniQure N.V. will post ($3.16) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/08/12/uniqure-n-v-qure-upgraded-to-hold-at-valuengine-updated-updated.html.
In other uniQure N.V. news, insider Harald Petry sold 49,300 shares of the stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $6.02, for a total transaction of $296,786.00. Following the transaction, the insider now directly owns 27,753 shares in the company, valued at approximately $167,073.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 173,460 shares of company stock worth $1,042,986 over the last 90 days. Company insiders own 0.64% of the company’s stock.
Several institutional investors have recently bought and sold shares of QURE. FMR LLC boosted its position in uniQure N.V. by 4.1% in the fourth quarter. FMR LLC now owns 1,175,118 shares of the biotechnology company’s stock worth $6,580,000 after buying an additional 46,200 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of uniQure N.V. by 6.8% in the fourth quarter. Renaissance Technologies LLC now owns 251,300 shares of the biotechnology company’s stock worth $1,407,000 after buying an additional 15,950 shares in the last quarter. Oxford Asset Management purchased a new position in shares of uniQure N.V. during the first quarter worth about $100,000. JPMorgan Chase & Co. boosted its position in shares of uniQure N.V. by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock worth $253,000 after buying an additional 14,702 shares in the last quarter. Finally, P.A.W. Capital Corp purchased a new position in shares of uniQure N.V. during the first quarter worth about $867,000. Hedge funds and other institutional investors own 30.22% of the company’s stock.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.